ClinicalTrials.Veeva

Menu

Safety and Performance Study of the Reliance 4-Front Lead

Boston Scientific logo

Boston Scientific

Status

Completed

Conditions

Tachycardia

Treatments

Device: Reliance 4-Front lead implantation

Study type

Interventional

Funder types

Industry

Identifiers

NCT01772576
BSC-CDM00052753
C1830 (Other Grant/Funding Number)

Details and patient eligibility

About

The objective of this study is to gather data to establish the chronic safety, performance and effectiveness of the RELIANCE 4-FRONT™ Active Fixation Defibrillation Leads.

Full description

The RELIANCE 4-FRONT Defibrillation Lead Post Market Clinical Follow-Up Study is a prospective, non-randomized, multi-center, single-group, post market clinical study to establish the chronic safety, performance and effectiveness of the RELIANCE 4-FRONT active fixation defibrillation leads.

A total of 167 patients (including 10 % attrition) are required to evaluate the Primary Endpoint.

Up to 20 Investigational centers located in Europe and Asia Pacific. Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.

Lead-related complications associated with the RELIANCE 4-FRONT active fixation lead will count toward this endpoint.

Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant.

Lead-related complications associated with the RELIANCE 4-FRONT active fixation lead will count toward this endpoint.

  • Lead-related Complication-Free Rate from 3 Months through 24 Months Post-Implant
  • Pacing Threshold at 0.5 ms pulse width at 3 Months Post-Implant
  • Sensed Amplitude at 3 Months Post-Implant
  • Pacing Impedance at 3 Months Post-Implant All endpoints will be assessed for the RELIANCE 4-FRONT active fixation lead.

Clinic visits will occur at:

  • Enrollment Visit (no later than 30 days prior to implant procedure)
  • Implant Procedure (Day 0; all future follow ups based on this date)
  • Pre-Discharge Clinic Visit (3 - 72 hours post-implant)
  • One Month Clinic Visit (30±7 days)
  • 3 Month Clinic Visit (91 ± 21 days)
  • 6 Month Clinic Visit (180 ± 30 days)
  • 12 Month Clinic Visit (365 ± 45 days)
  • 18 Month Clinic Visit (545± 45 days)
  • 24 Month Clinic Visit (730 ± 45 days) The study will be considered completed after all subjects have completed the 24 Month follow-up and study completion is anticipated in 2015. Primary endpoint completion is anticipated after all subjects have completed the 3 Month follow-up visit. All study required visits will be completed during clinic visits.

Hypotheses testing in the RELIANCE 4-FRONT PMCF Study will use standard statistical methodology as specified more in detail in the protocol.

Enrollment

167 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Willing and capable of providing informed consent
  • Has an indication for implantation of a single or dual chamber ICD or CRT-D system in their respective geography
  • Subjects planned to be implanted with the RELIANCE 4-FRONT Active Fixation Lead
  • Willing and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol
  • Age 18 or above, or of legal age to give informed consent specific to state and national law

Exclusion criteria

  • Known or suspected sensitivity to Dexamethasone Acetate (DXA)
  • Mechanical tricuspid heart valve
  • Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:
  • Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits);
  • RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject);
  • Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations
  • Currently on the active heart transplant list
  • Documented life expectancy of less than 12 months
  • Women of childbearing potential who are or might be pregnant at the time of study enrollment (method of assessment upon physician discretion)
  • Currently requiring chronic dialysis

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

167 participants in 1 patient group

Reliance 4-Front
Experimental group
Description:
Single arm, all patients will be implanted with the Reliance 4-Front lead
Treatment:
Device: Reliance 4-Front lead implantation

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems